These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 20861741)

  • 1. Stavudine toxicity in women is the main reason for treatment change in a 3-year prospective cohort of adult patients started on first-line antiretroviral treatment in Uganda.
    Castelnuovo B; Kiragga A; Kamya MR; Manabe Y
    J Acquir Immune Defic Syndr; 2011 Jan; 56(1):59-63. PubMed ID: 20861741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon.
    Laurent C; Bourgeois A; Mpoudi-Ngolé E; Ciaffi L; Kouanfack C; Mougnutou R; Nkoué N; Calmy A; Koulla-Shiro S; Delaporte E
    AIDS Res Hum Retroviruses; 2008 Mar; 24(3):393-9. PubMed ID: 18327976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency of stavudine substitution due to toxicity in children receiving antiretroviral treatment in sub-Saharan Africa.
    Palmer M; Chersich M; Moultrie H; Kuhn L; Fairlie L; Meyers T
    AIDS; 2013 Mar; 27(5):781-5. PubMed ID: 23169331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda.
    Forna F; Liechty CA; Solberg P; Asiimwe F; Were W; Mermin J; Behumbiize P; Tong T; Brooks JT; Weidle PJ
    J Acquir Immune Defic Syndr; 2007 Apr; 44(4):456-62. PubMed ID: 17279048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline CD4 cell counts and outcomes among adult treatment naive HIV patients after taking fixed dose combination GPO-VIR-S and GPO-VIR-Z in Thailand.
    Kyaw NL; Thanachartwet V; Kiertiburanakul S; Desakorn V; Chamnanchanunt S; Chierakul W; Manosuthi W; Pitisuttithum P; Sungkanuparph S
    Southeast Asian J Trop Med Public Health; 2013 Mar; 44(2):232-43. PubMed ID: 23691633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Motives for change of first-line antiretroviral therapy regimens in an unselected cohort of HIV/AIDS patients at a major referral centre in South-west Cameroon.
    Dimala CA; Bechem NN; Aroke D; Kadia BM
    BMC Res Notes; 2017 Nov; 10(1):623. PubMed ID: 29183354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line antiretroviral drug discontinuations in children.
    Fortuin-de Smidt M; de Waal R; Cohen K; Technau KG; Stinson K; Maartens G; Boulle A; Igumbor EU; Davies MA
    PLoS One; 2017; 12(2):e0169762. PubMed ID: 28192529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.
    Mulenga V; Musiime V; Kekitiinwa A; Cook AD; Abongomera G; Kenny J; Chabala C; Mirembe G; Asiimwe A; Owen-Powell E; Burger D; McIlleron H; Klein N; Chintu C; Thomason MJ; Kityo C; Walker AS; Gibb DM;
    Lancet Infect Dis; 2016 Feb; 16(2):169-79. PubMed ID: 26481928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of HIV-1 infection with a combination of nevirapine, stavudine, and lamivudine: a preliminary report on the Nigerian antiretroviral program.
    Idigbe EO; Adewole TA; Eisen G; Kanki P; Odunukwe NN; Onwujekwe DI; Audu RA; Araoyinbo ID; Onyewuche JI; Salu OB; Adedoyin JA; Musa AZ
    J Acquir Immune Defic Syndr; 2005 Sep; 40(1):65-9. PubMed ID: 16123684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An antiretroviral regimen containing 6 months of stavudine followed by long-term zidovudine for first-line HIV therapy is optimal in resource-limited settings: a prospective, multicenter study in China.
    Li T; Guo F; Li Y; Zhang C; Han Y; Lye W; He Y; Lu H; Xie J; Huang A; Li Y; Tang X; Wang H; Zhang T; Gao G; Lei J; Zhang X; Wu X; Sun Y; Bai J; Luo L; Wang H
    Chin Med J (Engl); 2014; 127(1):59-65. PubMed ID: 24384425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal Analysis of Adherence to First-Line Antiretroviral Therapy: Evidence of Treatment Sustainability from an Indian HIV Cohort.
    Shet A; Kumarasamy N; Poongulali S; Shastri S; Kumar DS; Rewari BB; Arumugam K; Antony J; De Costa A; D'Souza G
    Curr HIV Res; 2016; 14(1):71-9. PubMed ID: 26303008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of antiretroviral therapy in HIV-infected adults in the Department of Haematology, University Hospital of Brazzavllle, Congo].
    Dokekias AE; Galiba FO; Bokilo AD; Ntsimba P; Nsitou MB; Malanda F; Basseila GB
    Bull Soc Pathol Exot; 2008 Apr; 101(2):109-12. PubMed ID: 18543703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiretroviral treatment Long-Term (ALT) cohort: a prospective cohort of 10 years of ART-experienced patients in Uganda.
    Castelnuovo B; Mubiru F; Kiragga AN; Musomba R; Mbabazi O; Gonza P; Kambugu A; Ratanshi RP
    BMJ Open; 2018 Feb; 8(2):e015490. PubMed ID: 29467129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in clinical characteristics of HIV-infected patients initiating antiretroviral therapy in Shanghai from 2006 to 2011.
    Shen Y; Wang J; Qi T; Wang Z; Lu H
    Int J STD AIDS; 2014 Jun; 25(7):504-10. PubMed ID: 24327726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384.
    Dubé MP; Komarow L; Mulligan K; Grinspoon SK; Parker RA; Robbins GK; Roubenoff R; Tebas P;
    J Acquir Immune Defic Syndr; 2007 Aug; 45(5):508-14. PubMed ID: 17589373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study.
    French M; Amin J; Roth N; Carr A; Law M; Emery S; Drummond F; Cooper D;
    HIV Clin Trials; 2002; 3(3):177-85. PubMed ID: 12032876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort.
    Calmy A; Pinoges L; Szumilin E; Zachariah R; Ford N; Ferradini L;
    AIDS; 2006 May; 20(8):1163-9. PubMed ID: 16691068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reasons for first line ART modification over the years during the ART scale up in Uganda.
    Castelnuovo B; Mubiru F; Kalule I; Kiragga A
    AIDS Res Ther; 2019 Oct; 16(1):31. PubMed ID: 31597561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Demographic, socio-economic, behavioral and clinical factors predicting virologic failure with generic fixed-dose combination antiretroviral therapy before universal health insurance coverage in northern Thailand.
    Tsuchiya N; Pathipvanich P; Yasuda T; Mukoyama Y; Rojanawiwat A; Matsubayashi T; Saeng-aroon S; Auwanit W; Matsuyama A; Sawanpanyalert P; Ariyoshi K
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):71-82. PubMed ID: 19323037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-state models for the analysis of time-to-treatment modification among HIV patients under highly active antiretroviral therapy in Southwest Ethiopia.
    Birlie B; Braekers R; Awoke T; Kasim A; Shkedy Z
    BMC Infect Dis; 2017 Jun; 17(1):453. PubMed ID: 28655306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.